PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
